Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer [SUBSTUDY OF 700216591]

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 25 Nov 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

20 Nov 2024 Planned End Date changed from 1 Oct 2024 to 1 Dec 2024.
23 Mar 2023 Planned End Date changed from 1 May 2020 to 1 Oct 2024.
02 Sep 2022 Results assessing the impact of stromal tumor-infiltrating lymphocytes dynamics during neoadjuvant chemotherapy on pCR and survival in triple-negative early breast cancer, published in the Breast Cancer Research.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com